Serveur d'exploration sur la glutarédoxine

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Synthetic peptides based upon a three-dimensional model for the receptor recognition site of follicle-stimulating hormone exhibit antagonistic or agonistic activity at low concentrations.

Identifieur interne : 001277 ( Main/Exploration ); précédent : 001276; suivant : 001278

Synthetic peptides based upon a three-dimensional model for the receptor recognition site of follicle-stimulating hormone exhibit antagonistic or agonistic activity at low concentrations.

Auteurs : M. Hage-Van Noort [Pays-Bas] ; W C Puijk ; H H Plasman ; D. Kuperus ; W M Schaaper ; N J Beekman ; J A Grootegoed ; R H Meloen

Source :

RBID : pubmed:1315043

Descripteurs français

English descriptors

Abstract

Follicle-stimulating hormone (follitropin, FSH) belongs to a group of closely related glycoprotein hormones that contain two noncovalently linked dissimilar subunits designated alpha and beta. By using synthetic peptides, several receptor interaction sites in these hormones have been identified; however, the peptides have a reduced potency (lowest effective concentration of 10(-4) to 10(-5) M) relative to the hormone itself (10(-8) to 10(-11) M). This suggests that the peptides represent only a portion of a larger recognition site in the intact hormone that comprises parts of both the beta and the alpha chains. To develop peptides that exhibit FSH-antagonistic activity at low concentrations, we have constructed a three-dimensional model for FSH, which is based on an alignment of both the beta and the alpha chains of glycoprotein hormones with thioredoxin, for which x-ray diffraction data are available. This model resulted in the prediction of a conformational receptor-binding site in FSH, in which (parts of) three earlier proposed binding regions on the FSH molecule [namely, the regions FSH alpha-(34-37), with the amino acid sequence SRAY; FSH beta-(40-43), with the amino acid sequence TRDL; and FSH beta-(87-94), the "determinant loop" with the amino acid sequence CDSDSTDC] are located within 10 A of one another. On the basis of this model, peptides have been synthesized in which two of these binding regions are linked by a synthetic amino acid whose length was derived from the model, Ac-TDSDS-NH-(CH2)5-CO-SRAY-NH2 and Ac-SRAY-NH-(CH2)4-CO-TRDL-NH2. Both peptides inhibited FSH-induced cAMP production in Sertoli cells at 1000-fold lower concentrations (10(-7) M) than the peptides Ac-TRDL-NH2, Ac-SRAY-NH2, or Ac-TDSDS-NH2. In another peptide, Ac-TDSDS-NH-(CH2)5-CO-SRAY-NH-(CH2)4-CO-TRDL-NH2, all three binding regions have been linked. This peptide appeared to be a strong agonist of FSH action, as measured by the ability to stimulate cAMP production, at concentrations as low as 10(-7) M. The observation that a synthetic peptide, in which (parts of) three earlier described receptor interaction sites are combined according to the three-dimensional model, can mimic the action of FSH, at 10(-7) M, shows that this model is useful to predict a conformational receptor-binding site in FSH and that combination of only a few amino acid residues from the alpha and beta chains of FSH in a small synthetic peptide is sufficient to transduce a signal upon binding to the receptor.

DOI: 10.1073/pnas.89.9.3922
PubMed: 1315043
PubMed Central: PMC525603


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Synthetic peptides based upon a three-dimensional model for the receptor recognition site of follicle-stimulating hormone exhibit antagonistic or agonistic activity at low concentrations.</title>
<author>
<name sortKey="Hage Van Noort, M" sort="Hage Van Noort, M" uniqKey="Hage Van Noort M" first="M" last="Hage-Van Noort">M. Hage-Van Noort</name>
<affiliation wicri:level="1">
<nlm:affiliation>Central Veterinary Institute, Lelystad, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Central Veterinary Institute, Lelystad</wicri:regionArea>
<wicri:noRegion>Lelystad</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Puijk, W C" sort="Puijk, W C" uniqKey="Puijk W" first="W C" last="Puijk">W C Puijk</name>
</author>
<author>
<name sortKey="Plasman, H H" sort="Plasman, H H" uniqKey="Plasman H" first="H H" last="Plasman">H H Plasman</name>
</author>
<author>
<name sortKey="Kuperus, D" sort="Kuperus, D" uniqKey="Kuperus D" first="D" last="Kuperus">D. Kuperus</name>
</author>
<author>
<name sortKey="Schaaper, W M" sort="Schaaper, W M" uniqKey="Schaaper W" first="W M" last="Schaaper">W M Schaaper</name>
</author>
<author>
<name sortKey="Beekman, N J" sort="Beekman, N J" uniqKey="Beekman N" first="N J" last="Beekman">N J Beekman</name>
</author>
<author>
<name sortKey="Grootegoed, J A" sort="Grootegoed, J A" uniqKey="Grootegoed J" first="J A" last="Grootegoed">J A Grootegoed</name>
</author>
<author>
<name sortKey="Meloen, R H" sort="Meloen, R H" uniqKey="Meloen R" first="R H" last="Meloen">R H Meloen</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="1992">1992</date>
<idno type="RBID">pubmed:1315043</idno>
<idno type="pmid">1315043</idno>
<idno type="pmc">PMC525603</idno>
<idno type="doi">10.1073/pnas.89.9.3922</idno>
<idno type="wicri:Area/Main/Corpus">001284</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001284</idno>
<idno type="wicri:Area/Main/Curation">001284</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001284</idno>
<idno type="wicri:Area/Main/Exploration">001284</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Synthetic peptides based upon a three-dimensional model for the receptor recognition site of follicle-stimulating hormone exhibit antagonistic or agonistic activity at low concentrations.</title>
<author>
<name sortKey="Hage Van Noort, M" sort="Hage Van Noort, M" uniqKey="Hage Van Noort M" first="M" last="Hage-Van Noort">M. Hage-Van Noort</name>
<affiliation wicri:level="1">
<nlm:affiliation>Central Veterinary Institute, Lelystad, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Central Veterinary Institute, Lelystad</wicri:regionArea>
<wicri:noRegion>Lelystad</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Puijk, W C" sort="Puijk, W C" uniqKey="Puijk W" first="W C" last="Puijk">W C Puijk</name>
</author>
<author>
<name sortKey="Plasman, H H" sort="Plasman, H H" uniqKey="Plasman H" first="H H" last="Plasman">H H Plasman</name>
</author>
<author>
<name sortKey="Kuperus, D" sort="Kuperus, D" uniqKey="Kuperus D" first="D" last="Kuperus">D. Kuperus</name>
</author>
<author>
<name sortKey="Schaaper, W M" sort="Schaaper, W M" uniqKey="Schaaper W" first="W M" last="Schaaper">W M Schaaper</name>
</author>
<author>
<name sortKey="Beekman, N J" sort="Beekman, N J" uniqKey="Beekman N" first="N J" last="Beekman">N J Beekman</name>
</author>
<author>
<name sortKey="Grootegoed, J A" sort="Grootegoed, J A" uniqKey="Grootegoed J" first="J A" last="Grootegoed">J A Grootegoed</name>
</author>
<author>
<name sortKey="Meloen, R H" sort="Meloen, R H" uniqKey="Meloen R" first="R H" last="Meloen">R H Meloen</name>
</author>
</analytic>
<series>
<title level="j">Proceedings of the National Academy of Sciences of the United States of America</title>
<idno type="ISSN">0027-8424</idno>
<imprint>
<date when="1992" type="published">1992</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Amino Acid Sequence (MeSH)</term>
<term>Animals (MeSH)</term>
<term>Binding Sites (MeSH)</term>
<term>Chorionic Gonadotropin (chemistry)</term>
<term>Cyclic AMP (biosynthesis)</term>
<term>Drug Design (MeSH)</term>
<term>Follicle Stimulating Hormone (analogs & derivatives)</term>
<term>Follicle Stimulating Hormone (antagonists & inhibitors)</term>
<term>Follicle Stimulating Hormone (metabolism)</term>
<term>Glutaredoxins (MeSH)</term>
<term>In Vitro Techniques (MeSH)</term>
<term>Male (MeSH)</term>
<term>Molecular Sequence Data (MeSH)</term>
<term>Oxidoreductases (MeSH)</term>
<term>Protein Conformation (MeSH)</term>
<term>Proteins (chemistry)</term>
<term>Rats (MeSH)</term>
<term>Receptors, FSH (chemistry)</term>
<term>Receptors, FSH (metabolism)</term>
<term>Sertoli Cells (metabolism)</term>
<term>Structure-Activity Relationship (MeSH)</term>
<term>Thioredoxins (chemistry)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>AMP cyclique (biosynthèse)</term>
<term>Animaux (MeSH)</term>
<term>Cellules de Sertoli (métabolisme)</term>
<term>Conception de médicament (MeSH)</term>
<term>Conformation des protéines (MeSH)</term>
<term>Données de séquences moléculaires (MeSH)</term>
<term>Glutarédoxines (MeSH)</term>
<term>Gonadotrophine chorionique (composition chimique)</term>
<term>Hormone folliculostimulante (analogues et dérivés)</term>
<term>Hormone folliculostimulante (antagonistes et inhibiteurs)</term>
<term>Hormone folliculostimulante (métabolisme)</term>
<term>Mâle (MeSH)</term>
<term>Oxidoreductases (MeSH)</term>
<term>Protéines (composition chimique)</term>
<term>Rats (MeSH)</term>
<term>Relation structure-activité (MeSH)</term>
<term>Récepteur FSH (composition chimique)</term>
<term>Récepteur FSH (métabolisme)</term>
<term>Sites de fixation (MeSH)</term>
<term>Séquence d'acides aminés (MeSH)</term>
<term>Techniques in vitro (MeSH)</term>
<term>Thiorédoxines (composition chimique)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en">
<term>Follicle Stimulating Hormone</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en">
<term>Follicle Stimulating Hormone</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en">
<term>Cyclic AMP</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en">
<term>Chorionic Gonadotropin</term>
<term>Proteins</term>
<term>Receptors, FSH</term>
<term>Thioredoxins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>Follicle Stimulating Hormone</term>
<term>Receptors, FSH</term>
</keywords>
<keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr">
<term>Hormone folliculostimulante</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr">
<term>Hormone folliculostimulante</term>
</keywords>
<keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr">
<term>AMP cyclique</term>
</keywords>
<keywords scheme="MESH" qualifier="composition chimique" xml:lang="fr">
<term>Gonadotrophine chorionique</term>
<term>Protéines</term>
<term>Récepteur FSH</term>
<term>Thiorédoxines</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>Sertoli Cells</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr">
<term>Cellules de Sertoli</term>
<term>Hormone folliculostimulante</term>
<term>Récepteur FSH</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Amino Acid Sequence</term>
<term>Animals</term>
<term>Binding Sites</term>
<term>Drug Design</term>
<term>Glutaredoxins</term>
<term>In Vitro Techniques</term>
<term>Male</term>
<term>Molecular Sequence Data</term>
<term>Oxidoreductases</term>
<term>Protein Conformation</term>
<term>Rats</term>
<term>Structure-Activity Relationship</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Animaux</term>
<term>Conception de médicament</term>
<term>Conformation des protéines</term>
<term>Données de séquences moléculaires</term>
<term>Glutarédoxines</term>
<term>Mâle</term>
<term>Oxidoreductases</term>
<term>Rats</term>
<term>Relation structure-activité</term>
<term>Sites de fixation</term>
<term>Séquence d'acides aminés</term>
<term>Techniques in vitro</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Follicle-stimulating hormone (follitropin, FSH) belongs to a group of closely related glycoprotein hormones that contain two noncovalently linked dissimilar subunits designated alpha and beta. By using synthetic peptides, several receptor interaction sites in these hormones have been identified; however, the peptides have a reduced potency (lowest effective concentration of 10(-4) to 10(-5) M) relative to the hormone itself (10(-8) to 10(-11) M). This suggests that the peptides represent only a portion of a larger recognition site in the intact hormone that comprises parts of both the beta and the alpha chains. To develop peptides that exhibit FSH-antagonistic activity at low concentrations, we have constructed a three-dimensional model for FSH, which is based on an alignment of both the beta and the alpha chains of glycoprotein hormones with thioredoxin, for which x-ray diffraction data are available. This model resulted in the prediction of a conformational receptor-binding site in FSH, in which (parts of) three earlier proposed binding regions on the FSH molecule [namely, the regions FSH alpha-(34-37), with the amino acid sequence SRAY; FSH beta-(40-43), with the amino acid sequence TRDL; and FSH beta-(87-94), the "determinant loop" with the amino acid sequence CDSDSTDC] are located within 10 A of one another. On the basis of this model, peptides have been synthesized in which two of these binding regions are linked by a synthetic amino acid whose length was derived from the model, Ac-TDSDS-NH-(CH2)5-CO-SRAY-NH2 and Ac-SRAY-NH-(CH2)4-CO-TRDL-NH2. Both peptides inhibited FSH-induced cAMP production in Sertoli cells at 1000-fold lower concentrations (10(-7) M) than the peptides Ac-TRDL-NH2, Ac-SRAY-NH2, or Ac-TDSDS-NH2. In another peptide, Ac-TDSDS-NH-(CH2)5-CO-SRAY-NH-(CH2)4-CO-TRDL-NH2, all three binding regions have been linked. This peptide appeared to be a strong agonist of FSH action, as measured by the ability to stimulate cAMP production, at concentrations as low as 10(-7) M. The observation that a synthetic peptide, in which (parts of) three earlier described receptor interaction sites are combined according to the three-dimensional model, can mimic the action of FSH, at 10(-7) M, shows that this model is useful to predict a conformational receptor-binding site in FSH and that combination of only a few amino acid residues from the alpha and beta chains of FSH in a small synthetic peptide is sufficient to transduce a signal upon binding to the receptor.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">1315043</PMID>
<DateCompleted>
<Year>1992</Year>
<Month>05</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2019</Year>
<Month>05</Month>
<Day>01</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0027-8424</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>89</Volume>
<Issue>9</Issue>
<PubDate>
<Year>1992</Year>
<Month>May</Month>
<Day>01</Day>
</PubDate>
</JournalIssue>
<Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
<ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation>
</Journal>
<ArticleTitle>Synthetic peptides based upon a three-dimensional model for the receptor recognition site of follicle-stimulating hormone exhibit antagonistic or agonistic activity at low concentrations.</ArticleTitle>
<Pagination>
<MedlinePgn>3922-6</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Follicle-stimulating hormone (follitropin, FSH) belongs to a group of closely related glycoprotein hormones that contain two noncovalently linked dissimilar subunits designated alpha and beta. By using synthetic peptides, several receptor interaction sites in these hormones have been identified; however, the peptides have a reduced potency (lowest effective concentration of 10(-4) to 10(-5) M) relative to the hormone itself (10(-8) to 10(-11) M). This suggests that the peptides represent only a portion of a larger recognition site in the intact hormone that comprises parts of both the beta and the alpha chains. To develop peptides that exhibit FSH-antagonistic activity at low concentrations, we have constructed a three-dimensional model for FSH, which is based on an alignment of both the beta and the alpha chains of glycoprotein hormones with thioredoxin, for which x-ray diffraction data are available. This model resulted in the prediction of a conformational receptor-binding site in FSH, in which (parts of) three earlier proposed binding regions on the FSH molecule [namely, the regions FSH alpha-(34-37), with the amino acid sequence SRAY; FSH beta-(40-43), with the amino acid sequence TRDL; and FSH beta-(87-94), the "determinant loop" with the amino acid sequence CDSDSTDC] are located within 10 A of one another. On the basis of this model, peptides have been synthesized in which two of these binding regions are linked by a synthetic amino acid whose length was derived from the model, Ac-TDSDS-NH-(CH2)5-CO-SRAY-NH2 and Ac-SRAY-NH-(CH2)4-CO-TRDL-NH2. Both peptides inhibited FSH-induced cAMP production in Sertoli cells at 1000-fold lower concentrations (10(-7) M) than the peptides Ac-TRDL-NH2, Ac-SRAY-NH2, or Ac-TDSDS-NH2. In another peptide, Ac-TDSDS-NH-(CH2)5-CO-SRAY-NH-(CH2)4-CO-TRDL-NH2, all three binding regions have been linked. This peptide appeared to be a strong agonist of FSH action, as measured by the ability to stimulate cAMP production, at concentrations as low as 10(-7) M. The observation that a synthetic peptide, in which (parts of) three earlier described receptor interaction sites are combined according to the three-dimensional model, can mimic the action of FSH, at 10(-7) M, shows that this model is useful to predict a conformational receptor-binding site in FSH and that combination of only a few amino acid residues from the alpha and beta chains of FSH in a small synthetic peptide is sufficient to transduce a signal upon binding to the receptor.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hage-van Noort</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Central Veterinary Institute, Lelystad, The Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Puijk</LastName>
<ForeName>W C</ForeName>
<Initials>WC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Plasman</LastName>
<ForeName>H H</ForeName>
<Initials>HH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kuperus</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Schaaper</LastName>
<ForeName>W M</ForeName>
<Initials>WM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Beekman</LastName>
<ForeName>N J</ForeName>
<Initials>NJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Grootegoed</LastName>
<ForeName>J A</ForeName>
<Initials>JA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Meloen</LastName>
<ForeName>R H</ForeName>
<Initials>RH</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
<NlmUniqueID>7505876</NlmUniqueID>
<ISSNLinking>0027-8424</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006063">Chorionic Gonadotropin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054477">Glutaredoxins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011506">Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011962">Receptors, FSH</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>52500-60-4</RegistryNumber>
<NameOfSubstance UI="D013879">Thioredoxins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9002-68-0</RegistryNumber>
<NameOfSubstance UI="D005640">Follicle Stimulating Hormone</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>E0399OZS9N</RegistryNumber>
<NameOfSubstance UI="D000242">Cyclic AMP</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.-</RegistryNumber>
<NameOfSubstance UI="D010088">Oxidoreductases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="ErratumIn">
<RefSource>Proc Natl Acad Sci U S A 1993 Dec 15;90(24):12056</RefSource>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006063" MajorTopicYN="N">Chorionic Gonadotropin</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000242" MajorTopicYN="N">Cyclic AMP</DescriptorName>
<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015195" MajorTopicYN="N">Drug Design</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005640" MajorTopicYN="Y">Follicle Stimulating Hormone</DescriptorName>
<QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D054477" MajorTopicYN="N">Glutaredoxins</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D010088" MajorTopicYN="Y">Oxidoreductases</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011962" MajorTopicYN="N">Receptors, FSH</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D012708" MajorTopicYN="N">Sertoli Cells</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D013879" MajorTopicYN="N">Thioredoxins</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="pubmed">
<Year>1992</Year>
<Month>5</Month>
<Day>1</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>1992</Year>
<Month>5</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>1992</Year>
<Month>5</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">1315043</ArticleId>
<ArticleId IdType="pmc">PMC525603</ArticleId>
<ArticleId IdType="doi">10.1073/pnas.89.9.3922</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>J Biol Chem. 1975 Nov 25;250(22):8818-23</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">171267</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cell Endocrinol. 1980 Nov;20(2):113-26</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">6160070</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Endocrinology. 1990 May;126(5):2555-60</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1691699</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Endocrinology. 1990 Aug;127(2):573-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1695564</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 1991 Feb 15;266(5):2759-62</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1899663</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biochemistry. 1990 Feb 6;29(5):1194-200</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2108722</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Mol Biol. 1990 Mar 5;212(1):167-84</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2181145</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nucleic Acids Res. 1990 Apr 25;18(8):2175</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2336396</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biochemistry. 1985 Apr 9;24(8):1953-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2410022</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Recent Prog Horm Res. 1987;43:383-429</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2442804</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>FASEB J. 1988 Aug;2(11):2661-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2456242</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 1989 Aug 4;245(4917):494-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2502842</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 1989 Dec 22;246(4937):1620-2</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2556796</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biochem Biophys Res Commun. 1989 Dec 29;165(3):1250-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2610690</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biol Reprod. 1989 Jan;40(1):48-53</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2647161</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 1989 Apr 25;264(12):6705-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2708337</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Pept Protein Res. 1988 Jan;31(1):86-97</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2896637</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biochemistry. 1986 May 6;25(9):2644-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">3013310</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biochemistry. 1988 Jan 26;27(2):666-71</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">3126813</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Endocrinol. 1987 Oct;1(10):717-23</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">3155259</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cell Endocrinol. 1988 May;57(1-2):17-23</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">3396756</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 1987 Apr;84(7):2038-42</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">3470775</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 1987 Oct 5;262(28):13409-16</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">3654620</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cell Endocrinol. 1985 Aug;42(1):39-48</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">3928417</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biochem Soc Trans. 1974;2(5):915-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">4448287</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 1982 Jul 25;257(14):8368-71</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">6177696</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Methods Enzymol. 1983;91:524-45</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">6855599</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cell Endocrinol. 1975 Jul;3(1):57-70</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">168104</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 1990 Mar 25;265(9):5037-42</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1690733</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Endocrinology. 1990 Aug;127(2):658-66</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1695567</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 1990 Jan 5;247(4938):61-4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2104678</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Endocrinol. 1990 Apr;4(4):525-30</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2126341</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 1990 Jun;87(11):4396-400</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2349245</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 1987 Mar 15;262(8):3891-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2434506</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biol Reprod. 1989 Jan;40(1):13-26</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2493820</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 1989 Aug 4;245(4917):525-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2502844</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 1989 Nov 25;264(33):19716-29</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2584190</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 1989 Aug 25;264(24):13963-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2668278</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Endocrinol. 1989 Mar;3(3):526-31</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2747659</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 1988 Jan 1;239(4835):72-4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">3122320</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Endocrinol. 1988 Sep;2(9):806-15</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">3139991</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biochemistry. 1988 Dec 13;27(25):8939-44</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">3233214</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cell Endocrinol. 1987 Jan;49(1):51-62</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">3549388</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Annu Rev Biochem. 1985;54:237-71</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">3896121</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biochim Biophys Acta. 1984 Nov 26;767(2):248-56</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">6498180</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>Pays-Bas</li>
</country>
</list>
<tree>
<noCountry>
<name sortKey="Beekman, N J" sort="Beekman, N J" uniqKey="Beekman N" first="N J" last="Beekman">N J Beekman</name>
<name sortKey="Grootegoed, J A" sort="Grootegoed, J A" uniqKey="Grootegoed J" first="J A" last="Grootegoed">J A Grootegoed</name>
<name sortKey="Kuperus, D" sort="Kuperus, D" uniqKey="Kuperus D" first="D" last="Kuperus">D. Kuperus</name>
<name sortKey="Meloen, R H" sort="Meloen, R H" uniqKey="Meloen R" first="R H" last="Meloen">R H Meloen</name>
<name sortKey="Plasman, H H" sort="Plasman, H H" uniqKey="Plasman H" first="H H" last="Plasman">H H Plasman</name>
<name sortKey="Puijk, W C" sort="Puijk, W C" uniqKey="Puijk W" first="W C" last="Puijk">W C Puijk</name>
<name sortKey="Schaaper, W M" sort="Schaaper, W M" uniqKey="Schaaper W" first="W M" last="Schaaper">W M Schaaper</name>
</noCountry>
<country name="Pays-Bas">
<noRegion>
<name sortKey="Hage Van Noort, M" sort="Hage Van Noort, M" uniqKey="Hage Van Noort M" first="M" last="Hage-Van Noort">M. Hage-Van Noort</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/GlutaredoxinV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001277 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001277 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    GlutaredoxinV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:1315043
   |texte=   Synthetic peptides based upon a three-dimensional model for the receptor recognition site of follicle-stimulating hormone exhibit antagonistic or agonistic activity at low concentrations.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:1315043" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a GlutaredoxinV1 

Wicri

This area was generated with Dilib version V0.6.37.
Data generation: Wed Nov 18 15:13:42 2020. Site generation: Wed Nov 18 15:16:12 2020